ARAlexandria Real Estate Equities company profile
$43.84−1.04%Close 13 Nov 2026 · Market value $7.54B
About Alexandria Real Estate Equities
Alexandria Real Estate Equities, Inc. is a life science REIT that owns, operates, and develops collaborative Megacampus ecosystems in AAA life science innovation clusters, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of December 31, 2025, its North American portfolio comprised 340 properties with approximately 39.4 million RSF of operating and Class A/A+ development and redevelopment properties under construction, and its operating properties were 90.9% occupied. Tenants include multinational pharmaceutical companies, biotechnology companies, medical device and digital health companies, academic and medical research institutions, U.S. government research agencies, and venture capital firms. The company also makes investments in publicly traded and privately held life science entities.
A summary of the business section of the company's latest annual report, filed 26 Jan 2026.
Company facts
| Ticker | ARE · NYSE |
|---|
| Sector | Real estate |
|---|
| Industry | Office REITs |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1035443 |
|---|
| Latest annual report | 10-K, filed 26 Jan 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Joel S. Marcus | Executive Chairman · Director | 563K · < 1% | Open-market purchase, 11 Sep 2026 |
|---|
| Peter M. Moglia | Chief Executive Officer | 378K · < 1% | Shares withheld for tax, 30 Sep 2026 |
|---|
| Hunter L. Kass | Co-President and RMD | 237K · < 1% | Shares withheld for tax, 23 Jan 2026 |
|---|
| Marc E. Binda | CFO & Treasurer | 190K · < 1% | Sale under a 10b5-1 plan, 9 Jun 2026 |
|---|
| Lawrence J. Diamond | Co-Chief Operating Officer | 160K · < 1% | Disposition to the issuer, 23 Jan 2026 |
|---|
| John Hart Cole | Co-President, & Co-RMD | 109K · < 1% | Shares withheld for tax, 15 Sep 2026 |
|---|
| Michael A. Woronoff | Director | 21.4K · < 1% | Grant or award, 30 Sep 2026 |
|---|
| Richard H. Klein | Director | 15.7K · < 1% | Grant or award, 15 Jul 2026 |
|---|
| Maria C. Freire, PhD | Director | 10.9K · < 1% | Grant or award, 15 Jan 2026 |
|---|
| James P. Cain | Director | 7.2K · < 1% | Grant or award, 15 Jul 2026 |
|---|
| Sheila K. McGrath | Director | 6.3K · < 1% | Grant or award, 15 Oct 2026 |
|---|
| Claire Aldridge, PhD | Director | 4.5K · < 1% | Grant or award, 15 Jan 2026 |
|---|
| Hash Steve | Director | — | Grant or award, 15 Oct 2026 |
|---|
| Thomas Gregory Calvin | EVP - CTO | — | Shares withheld for tax, 15 Sep 2026 |
|---|
| Nelson Jesse J. | EVP - RMD | — | Shares withheld for tax, 15 Sep 2026 |
|---|
| Gossett Bret E. | EVP - Co-RMD | — | Shares withheld for tax, 15 Sep 2026 |
|---|
| Kuhn Hallie E. | EVP - Cap Market & Co-Lead -LS | — | Shares withheld for tax, 15 Sep 2026 |
|---|
| Foger Jenna R. | EVP - Co-Lead - Life Science | — | Shares withheld for tax, 15 Sep 2026 |
|---|
| Stevens Blake L. | Regional Market Director | — | Shares withheld for tax, 15 Sep 2026 |
|---|
| Boss Michael E. | Co-Regional Market Director | — | Shares withheld for tax, 15 Sep 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
ARE in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.